Obsidian Therapeutics, Inc. Common Stock Market Cap ($913.62 Million)
Market Cap & Net Worth: Obsidian Therapeutics, Inc. Common Stock (OBX)
Obsidian Therapeutics, Inc. Common Stock market cap. Obsidian Therapeutics, Inc. Common Stock (NASDAQ:OBX) has a market capitalization of $913.62 Million ($913.62 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8914 globally and #2559 in its home market, demonstrating a 6.10% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Obsidian Therapeutics, Inc. Common Stock's stock price $14.79 by its total outstanding shares 61772876 (61.77 Million). Also see Obsidian Therapeutics, Inc. Common Stock (OBX) cash conversion ratio for how efficiently the company converts equity into cash flow.
Obsidian Therapeutics, Inc. Common Stock Market Cap History (2026–2026)
Obsidian Therapeutics, Inc. Common Stock market cap history from 2026 to 2026. Data shows growth from $913.62 Million to $913.62 Million (0.00% CAGR). Check OBX stock price and chart for real-time trading data and today's change.
Obsidian Therapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Obsidian Therapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Obsidian Therapeutics, Inc. Common Stock (OBX) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of OBX by Market Capitalization
Companies near Obsidian Therapeutics, Inc. Common Stock in the global market cap rankings as of November 1, 2026. Also see Obsidian Therapeutics, Inc. Common Stock (OBX) total assets for a full breakdown of the balance sheet.
Key companies related to Obsidian Therapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Obsidian Therapeutics, Inc. Common Stock (2026–2026)
Market capitalization of Obsidian Therapeutics, Inc. Common Stock from 2026 to today. Between 2026 and today, Obsidian Therapeutics, Inc. Common Stock's market cap moved from $913.62 Million to $ 913.62 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $913.62 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Obsidian Therapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $913.62 Million USD |
| MoneyControl | $913.62 Million USD |
| MarketWatch | $913.62 Million USD |
| marketcap.company | $913.62 Million USD |
| Reuters | $913.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Obsidian Therapeutics, Inc. Common Stock
Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer. It utilizes a proprietary Cytodriver technology platform de… Read more